The new Max SoloStar pen holds 900 units of Toujeo, more than any other long-acting insulin pen in the US. Credit: Sanofi.

Sanofi has secured approval from the US Food and Drug Administration (FDA) for its new long-acting insulin pen, Toujeo Max SoloStar, for diabetes patients.

Toujeo is 300units/ml of insulin glargine. The new high capacity device has the ability to hold 900 units of Toujeo and can dispense up to 160units/ml of the insulin glargine in one injection.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company expects that Max SoloStar’s higher capacity will result in a decrease in the number of pens prescribed to adults for Toujeo use. This will lead to reduced refills and associated copays.

In certain patients, the maximum 160units/ml dose is expected to minimise the number of injections required to deliver the necessary Toujeo dosage.

“The new high capacity device has the ability to hold 900 units of Toujeo and can dispense up to 160units/ml of the insulin glargine in one injection.”

Sanofi North America Diabetes and Cardiovascular head Michelle Carnahan said: “This new high capacity pen has a broader range of doses than the original SoloStar, delivering Toujeo, long-acting insulin with established safety and efficacy.

“By reducing the number of injections for people who need more long-acting insulin and lowering copay costs – both of which are important to patients – Toujeo Max SoloStar underscores Sanofi’s continued commitment to help those living with diabetes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Toujeo Max SoloStar will be introduced in retail pharmacies across the US in the third quarter of 2018.

The company has decided to retain the price of Toujeo Max SoloStar’s predecessor SoloStar and provide a savings programme to make the new insulin pen variant financially accessible for patients.

Additionally, support will be provided through the free Toujeo COACH programme for adults using SoloStar or Max SoloStar.